Similarly, previous studies have indicated that IL-8 confers resistance to EGFR-TKIs by increasing p-AKT (44), and IL-6 contributes to cisplatin resistance via activation of p-AKT and p-ERK in NSCLC (45). The gene discussed is IL6; the disease is non-small cell lung carcinoma.